Comprehensive Benchmarking of Outcomes after Anakinra Treatment for Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Smith Kungwankiattichai, Jordan Gauthier(Seattle Cancer Care Alliance), Bashi Ratterree, Andrew J. Portuguese(University of Washington), Sanjog Bastola(Oregon Health & Science University), Rachel Bixler, Alexandre V. Hirayama(University of Washington), Eva Medvedova(Oregon Health & Science University), Gabrielle Meyers(Oregon Health & Science University), Jenna Voutsinas(Fred Hutch Cancer Center), Staci Williamson(Oregon Health & Science University), Craig Okada(Oregon Health & Science University), Jennifer J. Huang(Stanford Medicine), Yein Jeon(University of Washington Medical Center), Jacqueline Trussell, Cheryl Stomberg, Xiancheng Wu, Andy Chen, Stephen EF Spurgeon, Manoj Rai, Richard T Maziarz, Dwight C Macero, Mazyar Shadman(University of Washington), Yang Qiao, Rebecca W Silbermann, Emily C. Liang, Jessica T. Leonard, Amrita Desai, Brandon Hayes-Lattin, Tanaya Shree(Memorial Sloan Kettering Cancer Center), Qian Vicky Wu(Fred Hutch Cancer Center), Erik L. Kimble(University of Washington)
Cited by 0
Related Papers
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
|New England Journal of Medicine|2022|457
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
|Blood|2017|217